Indian PM Visit an Opportunity to Resolve Trade Disagreements, Says Think Tank Paper
The summit planned for September between President Barack Obama and Indian Prime Minister Narendra Modi represents an important opportunity for both countries to bridge differences on trade rules and policy, said President of The National Bureau of Asian Research Richard…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
Ellings in a recent paper. The two sides have been pitted against each other in conflicts over localization barriers and alleged Indian intellectual property (IP) right violations. “The IP challenge from India, while not as significant in scope or scale as that from China, has its own worrisome components,” said Ellings. “The unpredictable use of compulsory licenses is particularly nettlesome for affected U.S. sectors, especially pharmaceuticals, where two-thirds of patented drugs are on a list of potential compulsory licenses.” Many U.S. industry and administration officials have lambasted India for failing to stop a pervasive pharmaceutical counterfeit industry in the country, but the Office of the U.S. Trade Representative (USTR) did not place India on the “priority watch list” during a recent review (see 14050101).